Organon & Co. (OGN) Set to Announce Earnings on Thursday

Organon & Co. (NYSE:OGN) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Organon & Co. to post earnings of $0.94 per share for the quarter. Organon & Co. has set its FY 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

Organon & Co. (NYSE:OGN) last issued its earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same period last year, the business earned $1.31 earnings per share. Organon & Co.’s quarterly revenue was down .1% compared to the same quarter last year. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Down 0.8 %

OGN opened at $17.21 on Thursday. The company has a market capitalization of $4.43 billion, a P/E ratio of 4.43, a P/E/G ratio of 0.78 and a beta of 0.84. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. The firm’s fifty day moving average price is $19.88 and its two-hundred day moving average price is $20.15. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 6.51%. The ex-dividend date of this dividend was Friday, August 16th. Organon & Co.’s dividend payout ratio is 28.79%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on OGN. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their price objective for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.